Sinovac VP reports 227,500 share ownership

SINOVAC BIOTECH LTD executive Li Jing, VP of Quality and Production, has filed an initial insider ownership report.

Accepted by SEC EDGAR 03/18/2026 - 08:34 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD executive Li Jing, VP of Quality and Production, has filed an initial insider ownership report. The filing shows direct ownership of 227,500 common shares, with no insider buy or sell transactions reported in this statement.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider LI JING (NMN)

Role VP, Quality and Production

Type	Security	Shares	Price	Value
Holding	Common shares, par value $0.001 per share	--	--	--

Holdings: Common shares, par value $0.001 per share — 227,500 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Li Jing's Form 3 filing for SINOVAC BIOTECH (SVA) show?

The Form 3 shows that Li Jing directly owns 227,500 common shares of SINOVAC BIOTECH LTD. It is an initial ownership statement and does not reflect any recent insider purchases or sales.

Did Li Jing buy or sell SINOVAC BIOTECH (SVA) shares in this Form 3?

No, the Form 3 does not report any buy or sell transactions. It only discloses Li Jing’s existing direct ownership of 227,500 common shares as required when becoming a reporting insider.

How many SINOVAC BIOTECH (SVA) shares does Li Jing directly own?

Li Jing directly owns 227,500 common shares of SINOVAC BIOTECH LTD following the reported position. This figure represents her reported holdings as an officer, not a newly executed trade.

What is Li Jing’s role at SINOVAC BIOTECH (SVA) in this ownership filing?

Li Jing is identified as VP, Quality and Production at SINOVAC BIOTECH LTD. As a company officer, she must report her equity holdings, which this Form 3 filing records for regulatory transparency.

Is Li Jing’s SINOVAC BIOTECH (SVA) ownership direct or indirect?

The filing classifies Li Jing’s ownership as direct, meaning the 227,500 common shares are held in her own name rather than through a trust, partnership, or other indirect entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LI JING (NMN)

(Last) (First) (Middle)

NO. 39, SHANGDI WEST ROAD

HAIDIAN DISTRICT

(Street)

BEIJING 100085

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Quality and Production

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	227,500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)